Treat-to-Target for Depression Explained
Treat-to-target for depression means setting a clear goal — remission — measuring symptoms regularly with a validated tool like the PHQ-9, and adjusting treatment until that goal is reached. Instead of starting a medication and waiting, the care team tracks the actual score over time and changes the plan when the numbers don't improve.
The idea is borrowed from how good primary care already manages chronic conditions. Nobody starts a blood pressure medication and simply hopes; they recheck the reading and titrate until it hits target. Treat-to-target applies that same discipline to depression, where "how are you feeling?" alone is too vague to steer treatment.
Treat-to-target is a structured way of managing depression built on three commitments:
It's the opposite of "set and forget," where a patient starts an antidepressant, gets a follow-up appointment in three months, and drifts if the first choice doesn't work.
These two words describe very different results, and treat-to-target depends on the distinction.
Response is progress; remission is the goal. Stopping at response is a common failure point, because residual symptoms are one of the strongest predictors of relapse. A patient who feels "better" but still scores in the moderate range is often still impaired — sleep, concentration, and function haven't fully recovered. Treat-to-target keeps the plan moving past response toward remission rather than declaring victory too early.
The most widely used tool in primary care is the PHQ-9, a nine-item questionnaire scored from 0 to 27 that maps directly onto the clinical criteria for depression. It takes a couple of minutes, patients can complete it themselves, and it is sensitive enough to detect change between visits. The GAD-7 plays the same role for anxiety, which frequently travels with depression.
What makes these tools useful for treat-to-target is repetition. A single score describes a moment; a series of scores describes a trajectory. Plotting the PHQ-9 over weeks shows whether treatment is working, stalling, or failing — the signal a clinician needs to act on. This is what people mean by measurement-based care: using validated, repeated measurement to drive treatment decisions rather than relying on the impression from one conversation.
Depression treatment is uncertain at the individual level. The first medication a patient tries often doesn't produce remission, and there is no reliable way to predict in advance who will respond to what. That reality has two possible responses.
The "set and forget" approach treats the first prescription as the answer and only revisits it if the patient happens to raise a problem at a distant follow-up. Patients who aren't improving fall silent, miss appointments, and disengage — and the gap goes unnoticed until it's a crisis or a dropout.
Treat-to-target assumes the first attempt might not work and builds in the checkpoints to catch it. Because symptoms are measured on a schedule, a stalled trajectory is visible early, while there's still time to adjust. The point isn't that the clinician is smarter; it's that the system surfaces the patients who need a change instead of waiting for them to surface themselves. Measurement turns an invisible problem into an actionable one.
Treat-to-target is a core principle of the Collaborative Care Model (CoCM), an evidence-based approach to delivering behavioral health inside primary care that is backed by more than 90 randomized controlled trials. In that model, a behavioral health care manager tracks each patient's PHQ-9 and GAD-7 scores in a registry, a consulting psychiatrist reviews the caseload and flags patients who aren't improving, and the primary care clinician adjusts treatment. The registry is what makes treat-to-target work at scale — it ensures that patients who aren't reaching target don't slip through, because someone is watching the trajectory of every patient, not just the ones who show up asking for help.
You don't need collaborative care to practice treat-to-target — an individual clinician can do it with a questionnaire and a follow-up schedule. But the model operationalizes it: measurement, review, and adjustment become routine steps rather than good intentions.
Treat-to-target is an approach that sets remission as the explicit goal, measures depression symptoms regularly with a validated tool like the PHQ-9, and adjusts treatment whenever the score isn't improving on schedule. It replaces starting a medication and waiting with active tracking and course-correction.
Remission means symptoms have largely resolved. On the PHQ-9, it is commonly defined as a score below 5. It is a higher bar than "response," which is typically a 50% reduction in symptoms but still leaves the patient with meaningful residual symptoms.
Measurement-based care is the practice of using validated, repeated symptom measurements — such as the PHQ-9 for depression or the GAD-7 for anxiety — to guide treatment decisions. Treat-to-target is measurement-based care applied toward a specific goal: reaching remission.
There is no single rule, but treat-to-target relies on measuring often enough to catch a stalled response early — commonly at each visit or on a regular interval during active treatment. Your care team decides the schedule based on severity and how treatment is going.
No. This is educational information about how depression care can be structured, not individualized medical advice. Decisions about medication, dosing, and treatment changes should be made with your own clinician.
